MD Pediatrix Medical Group, Inc.
Q3 2025 10-Q
Pediatrix Medical Group, Inc. (MD) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 3, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • Newly added risk: Medicaid Reform via One Big Beautiful Bill Act on July 4, 2025, imposing work requirements and increased patient cost-sharing, uncertain reimbursement impact
- • Most materially updated risk: Exit of office-based pediatric practices finalized by Dec 31, 2024, shifting focus to hospital-based and maternal-fetal medicine to reduce operational complexity and costs
Quarterly Financial SummaryXBRL
Revenue
$493M
▼ -3.6% YoY▲ +5.1% QoQ
Net Income
$72M
▲ +268.8% YoY▲ +82.6% QoQ
Operating Margin
13.8%
▲ +719bp YoY▲ +104bp QoQ
Net Margin
14.5%
▲ +1075bp YoY▲ +618bp QoQ
ROE
8.1%
Total Assets
$2.2B
EPS (Diluted)
$0.84
▲ +265.2% YoY▲ +82.6% QoQ
Operating Cash Flow
$137M
▲ +49.5% YoY▲ +0.1% QoQ
Source: XBRL data from Pediatrix Medical Group, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Pediatrix Medical Group, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.